company background image
BIM logo

bioMérieux ENXTPA:BIM Stock Report

Last Price

€106.60

Market Cap

€12.6b

7D

1.9%

1Y

17.8%

Updated

29 Oct, 2024

Data

Company Financials +

BIM Stock Overview

Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

BIM fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance4/6
Financial Health6/6
Dividends0/6

bioMérieux S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for bioMérieux
Historical stock prices
Current Share Price€106.60
52 Week High€111.50
52 Week Low€88.25
Beta0.19
11 Month Change-2.29%
3 Month Change9.11%
1 Year Change17.79%
33 Year Change-4.05%
5 Year Change44.25%
Change since IPO966.00%

Recent News & Updates

Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?

Oct 14
Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?

bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

Sep 26
bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Sep 08
bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

Aug 03
Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

Recent updates

Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?

Oct 14
Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?

bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

Sep 26
bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Sep 08
bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

Aug 03
Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

May 30
bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)

Apr 18
Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)

bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

Mar 31
bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 17
bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Mar 15
These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Jan 27
bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

Jan 06
bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Dec 16
A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Oct 23
These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

Oct 05
bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Sep 15
There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Sep 07
Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Jun 30
Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Jun 09
Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Mar 31
Is bioMérieux (EPA:BIM) Using Too Much Debt?

The Return Trends At bioMérieux (EPA:BIM) Look Promising

Feb 23
The Return Trends At bioMérieux (EPA:BIM) Look Promising

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Jan 27
Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

Dec 16
bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Oct 18
bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Sep 14
Is bioMérieux (EPA:BIM) Using Too Much Debt?

Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

Aug 11
Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Jul 23
An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Jul 05
Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

May 26
bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

May 11
Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

Apr 23
bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

Apr 09
bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Mar 25
bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Mar 13
Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Feb 08
I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Why We Like The Returns At bioMérieux (EPA:BIM)

Dec 21
Why We Like The Returns At bioMérieux (EPA:BIM)

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Dec 07
Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Nov 07
Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Is bioMérieux (EPA:BIM) A Risky Investment?

Oct 07
Is bioMérieux (EPA:BIM) A Risky Investment?

Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital

Sep 22
Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital

Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)

Sep 07
Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Aug 06
Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital

Jun 15
There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital

A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)

May 31
A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Apr 30
Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

bioMérieux (EPA:BIM) Could Easily Take On More Debt

Mar 28
bioMérieux (EPA:BIM) Could Easily Take On More Debt

The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested

Mar 13
The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Feb 25
Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns

Feb 09
If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns

If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late

Jan 20
If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late

Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?

Dec 30
Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Shareholder Returns

BIMFR Medical EquipmentFR Market
7D1.9%0.3%0.5%
1Y17.8%28.4%7.5%

Return vs Industry: BIM underperformed the French Medical Equipment industry which returned 28.4% over the past year.

Return vs Market: BIM exceeded the French Market which returned 7.5% over the past year.

Price Volatility

Is BIM's price volatile compared to industry and market?
BIM volatility
BIM Average Weekly Movement3.0%
Medical Equipment Industry Average Movement5.3%
Market Average Movement4.5%
10% most volatile stocks in FR Market9.6%
10% least volatile stocks in FR Market2.2%

Stable Share Price: BIM has not had significant price volatility in the past 3 months compared to the French market.

Volatility Over Time: BIM's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196313,696Pierre Bouludwww.biomerieux.com

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry.

bioMérieux S.A. Fundamentals Summary

How do bioMérieux's earnings and revenue compare to its market cap?
BIM fundamental statistics
Market cap€12.58b
Earnings (TTM)€411.30m
Revenue (TTM)€3.81b

30.6x

P/E Ratio

3.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIM income statement (TTM)
Revenue€3.81b
Cost of Revenue€1.69b
Gross Profit€2.12b
Other Expenses€1.71b
Earnings€411.30m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.49
Gross Margin55.72%
Net Profit Margin10.81%
Debt/Equity Ratio10.1%

How did BIM perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

24%

Payout Ratio